CS
BDTX icon

Candriam SCA’s Black Diamond Therapeutics BDTX Stock Holding History

Candriam SCA’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-540,009
Closed -$1.52M – 699
2023
Q4 		$1.52M Buy
540,009
+40,000
+8% +$93.8K 0.01% 533
2023
Q3 		$1.44M Hold
500,009
– – 0.01% 498
2023
Q2 		$2.53M Buy
+500,009
New +$1.02M 0.02% 461

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Candriam SCA's BDTX Position: Q1 2024 in Review

Candriam SCA sold out of Black Diamond Therapeutics (BDTX) in Q1 2024, closing a stake of 540,009 shares — an estimated $1.52M sold.

Candriam SCA first reported a position in BDTX in Q2 2023 and held it in 3 quarters. The position peaked at $2.53M in Q2 2023. 88 funds tracked by Wall St. Rank hold BDTX as of Q1 2024.

  • Candriam SCA reported no remaining Black Diamond Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Candriam SCA sold 540,009 Black Diamond Therapeutics shares in Q1 2024, an estimated $1.52M.
  • Candriam SCA first reported a position in Black Diamond Therapeutics in Q2 2023 and held it in 3 quarters.
  • Candriam SCA's Black Diamond Therapeutics position peaked at $2.53M in Q2 2023.
  • 88 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.